undamentalytics Newsletter
Sign in

Pelthos Therapeutics Inc. key statistics and ratios

In fiscal 2025, Pelthos Therapeutics Inc. had an operating margin of -193.1%, debt equal to 80.9% of equity and a current ratio of 2.05. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Gross margin—76.3%78.6%
Operating margin—−193.1%−133.4%
Net margin—−257.9%−199.5%
Free-cash-flow margin—−135.1%—
Return on assets−581.1%−65.8%−64.5%
Asset turnover—0.250.32
Current ratio0.342.051.98
Debt to equity—80.9%—
Interest cover (operating income ÷ interest)n/mn/mn/m
R&D as % of revenue—7.3%3.0%
SG&A as % of revenue—252.8%200.6%
Capital spending as % of revenue—0.6%—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $137m
Short-term assets $63mLonger-term assets $74m
What it owes, and who funded it · $139m
Short-term liabilities $32mLonger-term liabilities $107mShareholders' equity $-2m
  • Short-term assets cover short-term liabilities $63m of assets due within a year against $32m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $63m short-term assets against $107m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$58m against $7m of interest.

From Pelthos Therapeutics Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: BFRI vs PTHSCPIX vs PTHSIMCC vs PTHS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Pelthos Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pelthos Therapeutics Inc.